Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
N/A
1(25.0%)
4Total
Phase 2(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03053362Phase 2Completed

THINC-it Vortioxetine - Sensitivity to Change

Role: lead

NCT05047952Phase 2Completed

Vortioxetine for Post-COVID-19 Condition

Role: lead

NCT04209296Completed

Chart Review of Patients Undergoing Ketamine Infusions

Role: lead

NCT05029466Phase 2Completed

Psilocybin for Treatment-Resistant Depression

Role: lead

NCT02508493Completed

Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder

Role: lead

NCT04695405Completed

Pharmacogenetics Associated With IV Ketamine

Role: lead

NCT03939676Completed

Evaluating Motivation and Reward Mechanisms and Brain Substrates in Adults With Obesity

Role: lead

NCT03999567Not ApplicableCompleted

Validation Study: Mobile DSST on Cognition in Adults With MDD

Role: lead

All 8 trials loaded